Bigelow Investment Advisors LLC Lowers Holdings in Pfizer Inc. (NYSE:PFE)

Bigelow Investment Advisors LLC decreased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 44.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,917 shares of the biopharmaceutical company's stock after selling 13,305 shares during the quarter. Bigelow Investment Advisors LLC's holdings in Pfizer were worth $449,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC bought a new position in Pfizer during the fourth quarter valued at about $26,000. Gladius Capital Management LP grew its position in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 38,015 shares during the period. Sierra Ocean LLC bought a new position in Pfizer during the fourth quarter valued at about $34,000. Teachers Insurance & Annuity Association of America bought a new position in Pfizer during the third quarter valued at about $35,000. Finally, Joseph Group Capital Management grew its position in Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 771 shares during the period. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on PFE. Wolfe Research began coverage on shares of Pfizer in a research report on Friday, November 15th. They set an "underperform" rating and a $25.00 price target for the company. Guggenheim reiterated a "buy" rating and set a $33.00 target price on shares of Pfizer in a research report on Monday, February 10th. StockNews.com lowered shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 20th. Citigroup cut their target price on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Finally, Evercore ISI upgraded shares of Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer has an average rating of "Moderate Buy" and a consensus target price of $31.92.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.06% of the company's stock.

Pfizer Price Performance

Shares of Pfizer stock traded up $0.42 on Friday, reaching $26.32. The stock had a trading volume of 54,560,140 shares, compared to its average volume of 38,524,395. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a market cap of $149.14 billion, a P/E ratio of 18.66, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The business's 50 day moving average is $26.30 and its two-hundred day moving average is $27.42.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's revenue for the quarter was up 24.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.10 earnings per share. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.54%. Pfizer's dividend payout ratio (DPR) is 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.